Summary

Rosuvastatin did not improve cardiovascular morbidity and mortality in patients who had end-stage renal disease and who were on hemodialysis, according to results of the large, randomized, placebo-controlled A Study to Evaluate the Use of Rosuvastatin in Subjects On Regular hemodialysis: an Assessment of Survival and Cardiovascular Events [AURORA; NCT00240331] trial. There was no difference between rosuvastatin 10 mg and placebo in reducing the combined endpoint of cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction or any of the individual components of this endpoint when analyzed separately.